A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Orally Administered IMG-004 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) and an Open-Label Study of Single Oral Dose of IMG-004 to Evaluate the Food Effect in Healthy Participants
Latest Information Update: 28 Jun 2024
At a glance
- Drugs IMG 004 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Inmagene
Most Recent Events
- 27 Jun 2024 Results presented in an Inmagene Media Release.
- 16 May 2024 Status changed from recruiting to completed.
- 08 Apr 2024 Number of treatment arms have been increased from 5 to 17 by the addition of 12 new arms for the SAD and MAD cohorts of Open-Label Study.